These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 6176167)
1. Monoclonal autoantibodies to acetylcholine receptors: evidence for a dominant idiotype and requirement of complement for pathogenicity. Lennon VA; Lambert EH Ann N Y Acad Sci; 1981; 377():77-96. PubMed ID: 6176167 [TBL] [Abstract][Full Text] [Related]
2. Spectrotypic analysis of antibodies to acetylcholine receptors in experimental autoimmune myasthenia gravis. Bionda A; De Baets MH; Tzartos SJ; Lindstrom JM; Weigle WO; Theophilopoulos AN Clin Exp Immunol; 1984 Jul; 57(1):41-50. PubMed ID: 6611231 [TBL] [Abstract][Full Text] [Related]
3. Pathological mechanisms in experimental autoimmune myasthenia gravis. II. Passive transfer of experimental autoimmune myasthenia gravis in rats with anti-acetylcholine recepotr antibodies. Lindstrom JM; Engel AG; Seybold ME; Lennon VA; Lambert EH J Exp Med; 1976 Sep; 144(3):739-53. PubMed ID: 182897 [TBL] [Abstract][Full Text] [Related]
4. Pathological mechanisms in experimental autoimmune myasthenia gravis. I. Immunogenicity of syngeneic muscle acetylcholine receptor and quantitative extraction of receptor and antibody-receptor complexes from muscles of rats with experimental automimmune myasthenia gravis. Lindstrom JM; Einarson BL; Lennon VA; Seybold ME J Exp Med; 1976 Sep; 144(3):726-38. PubMed ID: 182896 [TBL] [Abstract][Full Text] [Related]
5. Prevention of experimental autoimmune myasthenia gravis by manipulation of the immune network with a complementary peptide for the acetylcholine receptor. Araga S; LeBoeuf RD; Blalock JE Proc Natl Acad Sci U S A; 1993 Sep; 90(18):8747-51. PubMed ID: 8378359 [TBL] [Abstract][Full Text] [Related]
6. In vivo effects of neonatal administration of antiidiotype antibodies on experimental autoimmune myasthenia gravis. Verschuuren JJ; Graus YM; Van Breda Vriesman PJ; Tzartos S; De Baets MH Autoimmunity; 1991; 10(3):173-9. PubMed ID: 1756222 [TBL] [Abstract][Full Text] [Related]
7. Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune myasthenia gravis. Tüzün E; Scott BG; Goluszko E; Higgs S; Christadoss P J Immunol; 2003 Oct; 171(7):3847-54. PubMed ID: 14500686 [TBL] [Abstract][Full Text] [Related]
9. Use of complementary peptides and their antibodies in B-cell-mediated autoimmune disease: prevention of experimental autoimmune myasthenia gravis with a peptide vaccine. Araga S; Blalock JE Immunomethods; 1994 Oct; 5(2):130-5. PubMed ID: 7874437 [TBL] [Abstract][Full Text] [Related]
10. Analysis and modulation of the immune response of mice to acetylcholine receptor by anti-idiotypes. Souroujon MC; Barchan D; Fuchs S Immunol Lett; 1985; 9(6):331-6. PubMed ID: 3874156 [TBL] [Abstract][Full Text] [Related]
11. Paratope- and framework-related cross-reactive idiotopes on anti-acetylcholine receptor antibodies. Verschuuren JJ; Graus YM; Tzartos SJ; van Breda Vriesman PJ; De Baets MH J Immunol; 1991 Feb; 146(3):941-8. PubMed ID: 1988504 [TBL] [Abstract][Full Text] [Related]
12. Suppression of development of experimental autoimmune myasthenia gravis with isogeneic monoclonal anti-idiotopic antibody. Agius MA; Richman DP J Immunol; 1986 Oct; 137(7):2195-8. PubMed ID: 3489757 [TBL] [Abstract][Full Text] [Related]
13. beta-Bungarotoxin binding protein is immunogenic but lacks myasthenogenicity in rats. Qiao J; Wang ZY; Link H J Neurol Sci; 1994 Feb; 121(2):190-3. PubMed ID: 8158214 [TBL] [Abstract][Full Text] [Related]
14. Prevention of experimental autoimmune myasthenia gravis by a monoclonal antibody to a complementary peptide for the main immunogenic region of the acetylcholine receptors. Araga S; Galin FS; Kishimoto M; Adachi A; Blalock JB J Immunol; 1996 Jul; 157(1):386-92. PubMed ID: 8683141 [TBL] [Abstract][Full Text] [Related]
15. The immunopathology of myasthenia gravis. Lennon VA Hum Pathol; 1978 Sep; 9(5):541-51. PubMed ID: 309428 [TBL] [Abstract][Full Text] [Related]
16. Evidence against acetylcholine receptor having a main immunogenic region as target for autoantibodies in myasthenia gravis. Lennon VA; Griesmann GE Neurology; 1989 Aug; 39(8):1069-76. PubMed ID: 2474772 [TBL] [Abstract][Full Text] [Related]
17. Modulation of the anti-acetylcholine receptor response and experimental autoimmune myasthenia gravis by recombinant fragments of the acetylcholine receptor. Barchan D; Asher O; Tzartos SJ; Fuchs S; Souroujon MC Eur J Immunol; 1998 Feb; 28(2):616-24. PubMed ID: 9521072 [TBL] [Abstract][Full Text] [Related]
18. Sequence analysis of anti-AChR antibodies in experimental autoimmune myasthenia gravis. Graus Y; Meng F; Vincent A; van Breda Vriesman P; de Baets M J Immunol; 1995 Jun; 154(12):6382-96. PubMed ID: 7539019 [TBL] [Abstract][Full Text] [Related]
19. Experimental autoimmune myasthenia gravis in mice expressing human immunoglobulin loci. Stassen MH; Meng F; Melgert E; Machiels BM; Im SH; Fuchs S; Gerritsen AF; van Dijk MA; van de Winkel JG; De Baets MH J Neuroimmunol; 2003 Feb; 135(1-2):56-61. PubMed ID: 12576224 [TBL] [Abstract][Full Text] [Related]
20. Cyclosporine-induced syngeneic graft-vs-host disease: prevention of autoaggression by treatment with monoclonal antibodies to T lymphocyte cell surface determinants and to MHC class II antigens. Hess AD; Horwitz LR; Laulis MK; Fuchs E Clin Immunol Immunopathol; 1993 Dec; 69(3):341-50. PubMed ID: 7694818 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]